Minimally-invasive treatments for lower urinary tract symptoms in people with benign prostatic hyperplasia a review of clinical effectiveness

Benign prostatic hyperplasia or hypertrophy (BPH) refers to the enlargement of the prostate gland in men due to an overgrowth of cells. Although it is not a life-threatening condition, BPH causes serious morbidity in the form of lower urinary tract symptoms (LUTS) in an estimated 50% of men older th...

Full description

Bibliographic Details
Main Authors: Williams, D., Ryce, Andrea (Author)
Corporate Author: Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa Canadian Agency for Drugs and Technologies in Health August 29, 2019, 2019
Series:CADTH rapid response report: summary with critical appraisal
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:Benign prostatic hyperplasia or hypertrophy (BPH) refers to the enlargement of the prostate gland in men due to an overgrowth of cells. Although it is not a life-threatening condition, BPH causes serious morbidity in the form of lower urinary tract symptoms (LUTS) in an estimated 50% of men older than 75 years. For moderate to severe cases of LUTS that are unresponsive to medical management, surgery is the primary choice of treatment, the most common form being transurethral resection of the prostate (TURP). Prostatectomy (or a complete removal of the prostate) may be considered if the urethra is completely blocked or the prostate is extremely enlarged. To limit the occurrence of side effects, several minimally-invasive treatments have been developed. This review aims to summarize evidence regarding the clinical effectiveness of select minimally-invasive techniques for the treatment of LUTS associated with BPH.
Physical Description:1 PDF file (38 pages) illustration